The FDA has announced today that it “does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate”.  The-Rx’s the maker of Makena had previously sent “cease and desist” letters to pharmacies compounding this medication.

This is good news for patients and hopefully an important step towards a more reasonable price for this very important medication.

Read the full FDA announcement here.